EMA Said CHMP Recommended Ztalmy Received A Positive Opinion For Treatment Of Epileptic Seizures
Portfolio Pulse from Charles Gross
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Ztalmy for the treatment of epileptic seizures, according to Reuters.
May 26, 2023 | 11:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marinus Pharmaceuticals' Ztalmy receives positive opinion from EMA's CHMP for the treatment of epileptic seizures.
The positive opinion from EMA's CHMP for Ztalmy is a significant milestone for Marinus Pharmaceuticals (MRNS). This recommendation increases the likelihood of Ztalmy's approval in the European market, which could lead to increased revenues and a positive impact on MRNS's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100